noglo for hangover - strategy
DESCRIPTION
TRANSCRIPT
The first anti-hangover product that actually works.
NoGlo
2
TOC
NoGlo
NoGlo is the first product clinically demonstrated to reduce the toxins that cause hangovers from alcohol
A patented combination of specific amino acids, anti-oxidants and vitamins, NoGlo is all natural, with no caffeine or aspirin
3
Alcohol Metabolism
4
When you drink an alcoholic beverage, it contains ethanol, which causes intoxication
Your body breaks down ethanol into a compound called acetaldehyde, which accumulates
Acetaldehyde is 30 times as toxic as ethanol, a known carcinogen, causes inflammation, and is responsible for hangover symptoms like nausea and headache
How NoGlo Works 1) Take 2 capsules before you go out or
begin drinking (30min-1hour) 2) The compounds in NoGlo interact with
acetaldehyde directly, and speed up enzyme activity to clear it from the blood more quickly, limiting exposure
3) NoGlo significantly reduces acetaldehyde build-up when you drink, mitigating hangover before it ever occurs
4) Wake up without a bad hangover, not having to nurse one
5
Strategy There are no products on the market with
approved hangover claims by the FDA No products have demonstrated clinical efficacy
Hangover is an unarguably enormous market, with low competition Small, illegitimate competitors making unregulated
claims No large companies have been able to market a
hangover product because they are under the regulatory scrutiny of the FDA
6
Strategy NoGlo is in a unique position to be the first
product to have hangover claims approved by the FDA NoGlo can substantiate these claims through clinical
data
This represents enormous value to a large consumer products company looking to market and distribute a legitimate product with approved health claims
NoGlo will then license or sell the product, clinical substantiation, and IP to a strong company capable of rapidly and broadly commercializing the product to be the first product to pioneer the enormous market
7
Use of Funds NoGlo will conduct a clinical trial consisting
of 80 human subjects to complete FDA claim substantiation The trial will test for blood acetaldehyde levels over
time in normal individuals and will include reports of physical experience
The trial will have 2 simple groups: 1) placebo (40 subjects) and 2) NoGlo product (40 subjects)
Conducted by a sophisticated and established contract research organization and will cost $4-5K per subject
Filing International patent applications NoGlo has filed applications in the USA and a PCT
international application The PCT application needs to be filed in each
individual country of interest, which has associated filing fees and translation costs
8
Conclusion The anti-hangover market is filled with
illegitimate, small players, as no products can defend their efficacy and substantiate their claims
NoGlo presents a unique opportunity to make hangover claims which can actually be supported, providing the potential to market a product that can pioneer and dominate an enormous space
We will then look for a capable partner to commercialize, brand, and market the NoGlo product in the United States and globally, and capture this massive opportunity
9
NoGlo’s path to mitigating hangovers
Appendix 1
10
TOC
NoGlo’s Story San Francisco, California based clinical research
and nutraceutical development company
NoGlo was created to reduce Acetaldehyde accumulation during alcohol consumption in those with a metabolism disorder called Alcohol Flush Reaction
Established in 2012; NoGlo launched as a dietary supplement in the USA in November 2012
11
Alcohol Flush Reaction (AFR)
12
Caused by an inactive enzyme Acetaldehyde accumulates to very high
levelsAFR
Acetaldehyde is 30 times more toxic than alcohol
Accumulation of acetaldehyde leads to very unpleasant short-term effects and devastating long-term effects
X
The NoGlo Product NoGlo was formulated to reduce acetaldehyde
exposure when drinking alcoholic beverages, therefore reducing the symptoms of Alcohol Flush Reaction.
13
Composed only of ingredients already recognized as safe by the US FDA
Patented formulation of amino acids, vitamins, and anti-oxidants
Study Data – Blood Acetaldehyde
14
Conclusion:
NoGlo significantly reduces blood acetaldehyde following alcohol consumption in an IRB approved, internal-placebo controlled, double-blind, 20 human subject clinical trial
Acetaldehyde is very Toxic Acetaldehyde is 30 times as toxic as ethanol
Associated with consumption of alcohol, acetaldehyde is listed as a Group 1 human carcinogen by the International Agency for Research on Cancer (a division of WHO)
Acetaldehyde is a highly unstable compound and quickly forms free radical structures which can cause DNA, protein, and cell membrane damage
15
Why is this important?
Acetaldehyde is the cause of nausea, headache and other hangover symptoms and is responsible for the
oxidative damage that occurs due to alcohol
consumption16
A Dramatic Reduction in Hangover NoGlo reduces acetaldehyde accumulation by
22% after 20 minutes in those with AFR Acetaldehyde levels in those with AFR are 10x
those of normal individuals after 20 minutes Ethanol metabolism follows the same pathway in
those with AFR NoGlo’s mechanism of action is not specific to
AFR Hangovers are caused by a much lower
accumulation of acetaldehyde than AFR NoGlo has a much more dramatic impact on
lowering acetaldehyde accumulation in normal individuals
Acetaldehyde is the toxin that contributes to hangovers
NoGlo significantly reduces hangover symptoms
17
NoGlo Discovery
NoGlo is the first product to be clinically demonstrated to significantly reduce the toxins that contribute to a
hangover
18
Customer Discovery The following testimonials are from actual NoGlo
customers with AFR, discovering the anti-hangover benefits of NoGlo themselves: “I found that taking NoGlo really helped with the
hangovers” “…there is less of a hangover and less of the headache
while drinking which is more important to me than the red face.”
“Reduced hangover and less facial flushing when drinking alcohol – it’s as simple as that. Highly recommend it.”
“NoGlo definitely helps to reduce nausea and dizziness as well as preventing bad hangover.”
“…my hangovers are also reduced.” “NoGlo has helped a ton with my nausea and dizziness.”19
Hangover is a huge open market Alcohol consumption is ubiquitous both in the
United States and globally In 2012, US retail alcohol sales were $200 billion
Hangovers are an undeniably large problem According to the Center for Disease Control and
Prevention, hangovers cost the United States $160 billion in lost productivity per year
20
Low Competition Blowfish: a combination of caffeine and aspirin
used the morning after Blowfish is not supported by clinical evidence Blowfish, like others, aims at masking the symptoms
once they already occur. NoGlo mitigates hangover before it occurs, stopping the symptoms by stopping the damage that causes them
There are a number of small players that market themselves as hangover “cures” or “treatments” None have demonstrated efficacy Combination of drink, shot, and pill product Examples: PreFunc, Mercy drink, Sprayology, NoHo,
Drinkwel21
Why are there no big players? No products on the market are able to back up
their claims and demonstrate that they actually work There is a lot of illegitimacy in the anti-hangover space
and products that don’t do what they say they do, limiting their ability to capture the market
No products on the market have clinical evidence supporting their claims
NoGlo is the first scientifically-backed, legitimate, and proactive anti-hangover product, with clinical evidence to support its efficacy Other companies take small, one dimensional
approaches. NoGlo was tackling a HUGE acetaldehyde problem and took a big, multidimensional approach to solving the problem
22
Overview
NoGlo was designed to tackle an enormous
acetaldehyde problem: AFR. We stumbled onto an
enormous opportunity in another acetaldehyde
problem we were solving: Hangovers 23
Management and Formula
24
TOC
ManagementManagementSpencer GordonFounder & CEO
Mr. Gordon is the CEO and Founder of Gordon Health and NoGlo LLC. Through 18 months of research and collaboration with leading scientists in the areas of metabolism and biochemistry, Mr. Gordon developed the formulation for NoGlo. He has run the company since inception and has been responsible for all aspects of the business.
25
Board of DirectorsScott SmithChairman
Mr. Smith is the founder and Managing Partner of Viant Group, a Managing Director of Viant Capital and a founding member of Viant Green Capital. Mr. Smith has over twenty-five years of experience in investment banking, corporate law and company operations working primarily with technology, cleantech, media and healthcare companies.
Michael Gordon
Mr. Gordon is Vice President and co-founder of Apricorn, a computer security storage firm based in Poway, California. Established in 1983, Apricorn is the leading global provider of secure external storage solutions to OEM and Fortune 1000 companies. Mr. Gordon has interests in other private high-tech and biotech companies both as a founder and investor.
Bill Hake Mr. Hake is the Managing Partner at Hake Law and has spent 14 years as lead trial counsel at Prindle Decker and Amaro, and 6 years as a trial attorney and partner at Hassard, Bonnington, Rogers & Huber in San Francisco. Mr. Hake also served in the role of a prosecutor as an assistant district attorney for the City and County of San Francisco. Mr. Hake is rated "AV,” Martindale-Hubbell’s highest rating for attorneys.
Scientific Advisor
26
Scientific Advisors & Key Consultants
Ken Fujioka, MD
Dr. Ken Fujioka is an internal medicine practitioner with Scripps Clinic, whose clinical expertise centers around weight management, nutritional and metabolism disorders. Dr. Fujioka’s clinical research specialties include nutrition and metabolism, diabetes, and the metabolic syndrome. Dr. Fujioka is certified with the American Board of Internal Medicine and received his MD from University of Hawaii John Burns School of Medicine in 1983. Here is a link to a list of Dr. Fujioka’s publications on PubMed.
NoGlo Formulation Formula. Developed by Spencer Gordon over a
period of 2 years with consultation from department leaders at UC Berkeley in Biophysics and Biochemistry
Dosing. NoGlo is most effective if taken 30 min. – 1 hours before drinking
Ingredients. NoGlo’s ingredients are all already recognized as safe by the US FDA. Ingredients: Nicotinamide, N-Acetyl Cysteine, Vitamin C, Thiamine, Pantothenic Acid, Vitamin A, Alpha Lipoic Acid (full scientific background available)
Intellectual Property. Two PCT International patent applications have been filed, with claims supported by clinical data (applications available for review)
27